Post-transplant-cyclophosphamide and short-term Everolimus as graft-versus-host-prophylaxis in patients with relapsed/refractory lymphoma and myeloma—Final results of the phase II OCTET-EVER trial

The final results of the phase 2 OCTET-EVER trial—involving patients with relapsed/refractory lymphoid malignancies undergoing allogeneic HSCT using a calcineurin inhibitor–free approach consisting of post-transplant cyclophosphamide (PTCy) and short-term everolimus after reduced-intensity conditioning and matched peripheral blood stem cell transplantation—showed that using PTCy and short-term everolimus is safe and has low rates of acute GVHD and no severe acute GVHD or chronic GVHD, translating into a low rate of non-relapse mortality.